Comparison · NCT04859517-8ad02ef0
ADG20 IM - Cohort A vs Placebo IM - Cohort A: Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ADG20 IM - Cohort A vs Placebo IM - Cohort A: Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP). Trial comparisons, record NCT04859517-8ad02ef0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04859517-8ad02ef0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0.0000000000000000555 | 0.561 | wilson | |
| Risk in group 2 | 0.25 | 0.0889 | 0.532 | wilson | |
| Risk difference, group 1 minus group 2 | -0.25 | -0.532 | 0.334 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on ADG20 IM - Cohort A than on Placebo IM - Cohort A | 4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ADG20 IM - Cohort A | ADG20 IM - Cohort A is a post-exposure prophylaxis (PEP) arm where participants with no known history of SARS-CoV-2 infection and reported recent exposure (within 5 days) to SARS-CoV-2 were administered a single dose of ADG20 IM on Day 1. | 0 | 3 | OG000 |
| Group 2 | Placebo IM - Cohort A | Placebo IM - Cohort A is a post-exposure prophylaxis (PEP) arm where participants with no known history of SARS-CoV-2 infection and reported recent exposure (within 5 days) to SARS-CoV-2 were administered a single dose of placebo IM on Day 1. | 3 | 12 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Participants With at Least 1 COVID-19 Related Medically Attended Outpatient Visit (PEP)
- Description
Physician office, telemedicine, emergency room or urgent care center visits in participants with RT-PCR-confirmed symptomatic COVID-19 events, defined as having a central RT-PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms occurring within 14 days from the positive RT-PCR test sample collection, COVID-19-related hospitalization with a positive local or central SARS-CoV-2 test within 14 days, or all-cause death.
- Time frame
- Day 1 through Day 28 or emergence of Omicron (15-Dec-2021), whichever is earlier
- Population
Participants with RT-PCR confirmed symptomatic COVID-19 in the pre-Omicron modified Full Analysis Set-1 (mFAS-1): participants without current SARS-CoV-2 infection at baseline based on central tests (baseline RT-PCR-negative regardless of serostatus) randomized on or prior to 30-Nov-2021, allowing participants to be followed a minimum of 2 weeks through 15-Dec-2021 when Omicron became the predominant variant.
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of ADG20 for the Prevention of COVID-19
- NCT number
- NCT04859517
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19
- Interventions
- ADG20, Placebo
- Lead sponsor
- Invivyd, Inc.
- Results first posted
- 2024-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04859517?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04859517-8ad02ef0